Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medication Management LLC

Neither a doctor nor a teaching hospital

Research payments

$8,114,431

1,874 payments

Through program year 2025, Medication Management LLC is reported as receiving $8,114,431 in research payments, across 1,874 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,894,894 66
2024 Research $1,469,536 78
2023 Research $757,053 213
2022 Research $633,699 597
2021 Research $1,104,515 531
2020 Research $1,280,151 249
2019 Research $974,582 140

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,762,039 42 payments
  2. Novartis Pharmaceuticals Corporation $1,141,119 41 payments
  3. GlaxoSmithKline, LLC. $655,201 109 payments
  4. Amgen Inc. $413,988 17 payments
  5. Pfizer Inc. $360,809 71 payments
  6. AstraZeneca Pharmaceuticals LP $311,944 24 payments
  7. Esperion Therapeutics, Inc. $298,322 646 payments
  8. Janssen Research & Development, LLC $268,709 73 payments
  9. AbbVie, Inc. $268,649 180 payments
  10. Kowa Research Institute, Inc. $253,964 70 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $650,801 5 payments
  2. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $595,473 77 payments
  3. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $440,600 4 payments
  4. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $392,595 3 payments
  5. A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $315,968 2 payments
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $298,322 646 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $271,946 1 payment
  8. A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy $268,709 73 payments
  9. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $257,507 32 payments
  10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $249,558 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record